679 related articles for article (PubMed ID: 23120995)
1. [The intravesical recurrence after 3-day consecutive intravesical instillation of pirarubicine hydrochloride (THP) following transurethral resection of bladder tumor (TURBT) for non-muscle-invasive bladder cancer].
Tochigi T; Sakurada Y; Aoki H; Kawamura S; Itou S; Satou I; Tateno H
Nihon Hinyokika Gakkai Zasshi; 2012 Jul; 103(4):610-6. PubMed ID: 23120995
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.
Fujita N; Hatakeyama S; Momota M; Kido K; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2020 Aug; 38(8):684.e17-684.e24. PubMed ID: 32278732
[TBL] [Abstract][Full Text] [Related]
3. Prospective randomized controlled trial of postoperative early intravesical chemotherapy with pirarubicin (THP) for solitary non-muscle invasive bladder cancer comparing single and two-time instillation.
Tanimoto R; Saika T; Ebara S; Kobayashi Y; Nasu R; Yamada D; Takamoto H; Miyaji Y; Nasu Y; Tsushima T; Kumon H
World J Urol; 2018 Jun; 36(6):889-895. PubMed ID: 29387931
[TBL] [Abstract][Full Text] [Related]
4. [Value of European Organisation for Research and Treatment of Cancer score system for predication of immediate postoperative intravesical instillation of pirarubicin after transurethral resection of non-muscle invasive bladder cancer].
Ding XL; Yang DL; Yan RP; Li ZP; Ye CW; He J; Yu L; He SC; Li HD
Zhonghua Zhong Liu Za Zhi; 2018 Apr; 40(4):308-312. PubMed ID: 29730921
[No Abstract] [Full Text] [Related]
5. [Post-Operative Immediate Single Instillation of Chemotherapy as Prevention of Recurrence after Transurethral Resection of Intermediate-High Risk Non-Muscle-Invasive Bladder Cancer].
Sugiura S; Noto N; Koizumi M; Takamoto D; Fujikawa N; Ikeda I
Hinyokika Kiyo; 2018 Jul; 64(7):297-301. PubMed ID: 30089338
[TBL] [Abstract][Full Text] [Related]
6. Randomized study of intravesical pirarubicin chemotherapy with low and intermediate-risk nonmuscle-invasive bladder cancer in Japan: Comparison of a single immediate postoperative intravesical instillation with short-term adjuvant intravesical instillations after transurethral resection.
Naya Y; Mikami K; Takaha N; Inoue Y; Fujihara A; Kanazawa M; Nakanishi H; Miyashita H; Ukimura O
Medicine (Baltimore); 2018 Oct; 97(42):e12740. PubMed ID: 30334959
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of immediate instillation combined with regular instillations of pirarubicin for Ta and T1 transitional cell bladder cancer after transurethral resection: a prospective, randomized, multicenter study.
Li NC; Ye ZQ; Na YQ;
Chin Med J (Engl); 2013; 126(15):2805-9. PubMed ID: 23924446
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome of conservative therapy for stage T1, grade 3 transitional cell carcinoma of the bladder.
Hara I; Miyake H; Takechi Y; Eto H; Gotoh A; Fujisawa M; Okada H; Arakawa S; Kamidono S;
Int J Urol; 2003 Jan; 10(1):19-24. PubMed ID: 12534921
[TBL] [Abstract][Full Text] [Related]
9. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
[TBL] [Abstract][Full Text] [Related]
10. Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial.
Messing EM; Tangen CM; Lerner SP; Sahasrabudhe DM; Koppie TM; Wood DP; Mack PC; Svatek RS; Evans CP; Hafez KS; Culkin DJ; Brand TC; Karsh LI; Holzbeierlein JM; Wilson SS; Wu G; Plets M; Vogelzang NJ; Thompson IM
JAMA; 2018 May; 319(18):1880-1888. PubMed ID: 29801011
[TBL] [Abstract][Full Text] [Related]
11. [Post-Operative Single Immediate Intravesical Instillation Chemotherapy as Prophylaxis for Reccurence after Transurethral Resection of Low Risk Non-Muscle-Invasive Bladder Cancer].
Sugiura S; Noto N; Koizumi M; Takamoto D; Fujikawa N; Ikeda I
Hinyokika Kiyo; 2017 May; 63(5):183-187. PubMed ID: 28625024
[TBL] [Abstract][Full Text] [Related]
12. Intra-arterial chemotherapy combined with intravesical chemotherapy compared with intravesical BCG immunotherapy retrospectively in high-risk non-muscle-invasive bladder cancer after transurethral resection of the bladder tumor.
Huang B; Huang G; Li W; Chen L; Mao X; Chen J
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1781-1788. PubMed ID: 33222014
[TBL] [Abstract][Full Text] [Related]
13. The value of transurethral thulium laser en bloc resection combined with a single immediate postoperative intravesical instillation of pirarubicin in primary non-muscle-invasive bladder cancer.
Xu S; Tan S; Wu T; Gu J; Xu L; Che X
Lasers Med Sci; 2020 Oct; 35(8):1695-1701. PubMed ID: 31970565
[TBL] [Abstract][Full Text] [Related]
14. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial.
Ito A; Shintaku I; Satoh M; Ioritani N; Aizawa M; Tochigi T; Kawamura S; Aoki H; Numata I; Takeda A; Namiki S; Namima T; Ikeda Y; Kambe K; Kyan A; Ueno S; Orikasa K; Katoh S; Adachi H; Tokuyama S; Ishidoya S; Yamaguchi T; Arai Y
J Clin Oncol; 2013 Apr; 31(11):1422-7. PubMed ID: 23460707
[TBL] [Abstract][Full Text] [Related]
15. Efficacy analysis of a novel thermochemotherapy scheme with pirarubicin for intermediate- and high-risk nonmuscle-invasive bladder cancer: a single-institution nonrandomized concurrent controlled trial.
Zhou J; Li L; Li X; Yu Q; Cui S; Shu K; Liu J; Liu J; Ding D; Du T
Int J Hyperthermia; 2019; 36(1):868-875. PubMed ID: 31452420
[No Abstract] [Full Text] [Related]
16. A prospective comparison of intra-arterial chemotherapy combined with intravesical chemotherapy and intravesical chemotherapy alone after transurethral resection with a thulium laser in high-risk non-muscle invasive bladder cancer.
Sun F; Zhao R; Zhu Y; Cui D; Wang X; Han B; Liang S; Liu H; Sun X; Zhao F; Xu D; Xia S
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1099-1107. PubMed ID: 28421294
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of Intravesical Doxorubicin Immediately Following Resection of Primary Non-muscle-invasive Bladder Cancer: A Propensity Score-matched Analysis.
Fukuokaya W; Kimura T; Miki J; Kimura S; Watanabe H; Bo F; Okada D; Aikawa K; Ochi A; Suzuki K; Shiga N; Abe H; Egawa S
Clin Genitourin Cancer; 2020 Apr; 18(2):e55-e61. PubMed ID: 31630978
[TBL] [Abstract][Full Text] [Related]
18. Should intravesical Bacillus Calmette-Guerin (BCG) treatment be administered to patients with T0 after repeat transurethral resection of bladder tumor in patients with high-risk non-muscle invasive bladder cancer?
Yuk HD; Jeong CW; Kwak C; Kim HH; Ku JH
PLoS One; 2018; 13(11):e0208267. PubMed ID: 30496283
[TBL] [Abstract][Full Text] [Related]
19. [Mechanism of intravesical instillation of pirarubicin for preventing recurrence of non-muscle invasive bladder cancer].
Li Q; Xu T; Wang XF
Zhonghua Zhong Liu Za Zhi; 2009 Dec; 31(12):904-7. PubMed ID: 20193328
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of European Organization for Research and Treatment of Cancer (EORTC) risk tables for the prediction of recurrence and progression of non-muscle invasive bladder cancer after intravesical pirarubicin instillation].
Xu C; Jiang XZ; Zhang NZ; Ma L; Xu ZS
Zhonghua Zhong Liu Za Zhi; 2012 Aug; 34(8):609-12. PubMed ID: 23158996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
